It is now well established that PD-L1 is overexpressed in triple-negative breast cancers (TNBC), a subtype of breast cancer characterized by the lack of expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 receptor (HER2) [4,5]. Here, PGR is linked to breast carcinoma.